- Fannie Mae to Tighten Lending Standards: Report
- Share Trading on London Stock Exchange Resumes
- China Overcapacity Worsening, EU Chamber Warns
- Investing in Good Karma – and Making a Profit
- UK Retail Sales Pick Up in Nov., Strong Dec. Seen
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Wal-Mart Price Pressure Hurts China Workers: Report
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
MOST SHARED
- Chinese Overcapacity is Worsening, EU Chamber Warns
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- The Executive Job Search
- Gold Retreats from New High Above $1,194
- Hyundai-Kia Targets Rapid China Growth in 2010
- China Unveils Carbon Target Ahead of Copenhagen
- Black Friday: Bargain or Bust?
- Wal-Mart Price Pressure Hurts China Workers: Report
- Oil Friday
Text Size 
GlaxoSmithKline, [GSK
Loading...
()
] Europe's biggest drug maker, reported a 16% rise in annual profit Thursday, in line with expectations of analysts polled by Reuters. But the company said 2007 growth would slow as it awaits pipeline renewal.
Fourth-quarter profit before tax was $2.2 billion, up from $2.08 billion in the same three months ending December in 2005.
Sales in the fourth-quarter rose to $7.79 billion from $7.66 billion, helped by strong U.S. demand.
For the coming year, GSK forecast EPS growth in constant exchange rate terms of between 8% to 10% -- better than the low single-digit level some analysts had expected.
GSK said that it plans launch 5 major new pharmaceutical products in 2007:Tykerb, which is a breast cancer drug; Allermist/Avamys, a allergic rhinitis treatment; Coreg, for treating heart conditions and Trexima for migraines. The company also, said that it expects to file for U.S. approval for cervical cancer vaccine Cervarix in April.
Competition from generic drug makers will increase for major pharmaceuticals in 2007, and GSK is no exception with both its anti-nausea drug Zofran and anti-depressant Wellbutrin XL set to face new rivals.
The company's shares rose more than 1% in London in reaction to the results.
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Ever wished your cab driver would stop nattering and just get to where you're going? Well that moment is near(er).
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
Data is a real-time snapshot *Data is delayed at least 15 minutes